News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
343,835 Results
Type
Article (20901)
Company Profile (141)
Press Release (322782)
Multimedia
Podcasts (106)
Webinars (17)
Section
Business (105826)
Career Advice (890)
Deals (18627)
Drug Delivery (105)
Drug Development (51019)
Employer Resources (80)
FDA (7826)
Job Trends (7814)
News (186784)
Policy (17459)
Tag
Academia (737)
Accelerated approval (14)
Adcomms (22)
Allergies (73)
Alliances (27969)
ALS (83)
Alzheimer's disease (767)
Antibody-drug conjugate (ADC) (179)
Approvals (7952)
Artificial intelligence (253)
Autoimmune disease (60)
Automation (12)
Bankruptcy (178)
Best Places to Work (5554)
BIOSECURE Act (14)
Biosimilars (156)
Biotechnology (60)
Bladder cancer (70)
Brain cancer (32)
Breast cancer (231)
Cancer (2103)
Cardiovascular disease (217)
Career advice (736)
Career pathing (24)
CAR-T (99)
CDC (14)
Cell therapy (259)
Cervical cancer (11)
Clinical research (44477)
Collaboration (866)
Company closure (1)
Compensation (335)
Complete response letters (48)
COVID-19 (1144)
CRISPR (45)
C-suite (449)
Cystic fibrosis (85)
Data (2999)
Decentralized trials (2)
Denatured (26)
Depression (70)
Diabetes (229)
Diagnostics (1878)
Digital health (14)
Diversity (8)
Diversity, equity & inclusion (22)
Drug discovery (152)
Drug pricing (181)
Drug shortages (33)
Duchenne muscular dystrophy (124)
Earnings (40746)
Editorial (44)
Employer branding (10)
Employer resources (78)
Events (50632)
Executive appointments (608)
FDA (9211)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (4)
Funding (596)
Gene editing (82)
Generative AI (28)
Gene therapy (242)
GLP-1 (776)
Government (1997)
Grass and pollen (4)
Guidances (202)
Healthcare (5915)
HIV (25)
Huntington's disease (21)
IgA nephropathy (55)
Immunology and inflammation (154)
Immuno-oncology (23)
Indications (49)
Infectious disease (1266)
Inflammatory bowel disease (110)
Inflation Reduction Act (11)
Influenza (40)
Intellectual property (119)
Interviews (118)
IPO (7420)
IRA (52)
Job creations (2442)
Job search strategy (653)
Kidney cancer (10)
Labor market (58)
Layoffs (340)
Leadership (26)
Legal (4149)
Liver cancer (35)
Longevity (7)
Lung cancer (314)
Lymphoma (195)
Machine learning (19)
Management (31)
Manufacturing (456)
MASH (96)
Medical device (1995)
Medtech (2000)
Mergers & acquisitions (11681)
Metabolic disorders (795)
Multiple sclerosis (87)
NASH (20)
Neurodegenerative disease (144)
Neuropsychiatric disorders (59)
Neuroscience (1411)
NextGen: Class of 2025 (2360)
Non-profit (914)
Now hiring (41)
Obesity (459)
Opinion (226)
Ovarian cancer (58)
Pain (126)
Pancreatic cancer (82)
Parkinson's disease (141)
Partnered (16)
Patents (255)
Patient recruitment (185)
Peanut (19)
People (34303)
Pharmaceutical (76)
Pharmacy benefit managers (30)
Phase I (13990)
Phase II (18767)
Phase III (15101)
Pipeline (2117)
Policy (218)
Postmarket research (1620)
Preclinical (4915)
Press Release (29)
Prostate cancer (120)
Psychedelics (24)
Radiopharmaceuticals (171)
Rare diseases (452)
Real estate (3202)
Recruiting (33)
Regulatory (13476)
Reports (25)
Research institute (832)
Resumes & cover letters (140)
Rett syndrome (3)
RNA editing (9)
RSV (40)
Schizophrenia (108)
Series A (105)
Series B (74)
Service/supplier (7)
Sickle cell disease (61)
Special edition (21)
Spinal muscular atrophy (117)
Sponsored (18)
Startups (2034)
State (2)
Stomach cancer (11)
Supply chain (69)
Tariffs (91)
The Weekly (78)
Vaccines (382)
Venture capital (55)
Weight loss (341)
Women's health (32)
Worklife (8)
Date
Last 7 days (319)
Last 30 days (1199)
Last 365 days (15511)
2025 (15066)
2024 (17678)
2023 (19648)
2022 (25868)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15588)
2017 (17254)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (414)
Alabama (40)
Alaska (1)
Arizona (88)
Arkansas (8)
Asia (25724)
Australia (3308)
California (4417)
Canada (1713)
China (654)
Colorado (175)
Connecticut (187)
Delaware (165)
Europe (53151)
Florida (766)
Georgia (94)
Hawaii (1)
Idaho (18)
Illinois (398)
India (44)
Indiana (275)
Iowa (3)
Japan (270)
Kansas (81)
Kentucky (28)
Louisiana (5)
Maine (4)
Maryland (572)
Massachusetts (3594)
Michigan (62)
Minnesota (225)
Mississippi (3)
Missouri (40)
Montana (12)
Nebraska (12)
Nevada (35)
New Hampshire (8)
New Jersey (1744)
New Mexico (21)
New York (1219)
North Carolina (735)
North Dakota (2)
Northern California (2030)
Ohio (117)
Oklahoma (8)
Oregon (22)
Pennsylvania (985)
Puerto Rico (17)
Rhode Island (25)
South America (611)
South Carolina (10)
Southern California (1867)
Tennessee (61)
Texas (600)
United States (16923)
Utah (90)
Virginia (161)
Washington D.C. (57)
Washington State (349)
West Virginia (1)
Wisconsin (43)
Wyoming (1)
343,835 Results for "biohaven pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
November 12, 2025
·
3 min read
·
Dan Samorodnitsky
Rare diseases
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.
November 5, 2025
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
FDA Delays Decision Date on Biohaven’s Spinocerebellar Ataxia Application
The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.
May 15, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Reversals Send UniQure, Biohaven, Capricor, More Into a ‘Tailspin’
Since July, several biotechs have been forced to pivot as previous agreements with the FDA around evidence required for approval were reversed, a phenomenon that, according to experts, could portend a more restrictive regulator.
November 24, 2025
·
7 min read
·
Heather McKenzie
Press Releases
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
November 13, 2025
·
3 min read
Press Releases
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
November 10, 2025
·
13 min read
Mergers & acquisitions
Biohaven Grabs a Foothold With $600M Windfall From Oberland Capital
Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, which is currently under FDA review with a decision expected in the third quarter.
April 29, 2025
·
2 min read
·
Tristan Manalac
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
Drug pricing
UK Agrees To Boost Drug Spending by 25% To Avoid US Pharma Tariffs
U.K.-based pharmas will not face tariffs as long as Donald Trump is president, according to the agreement.
December 1, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
November 14, 2025
·
3 min read
1 of 34,384
Next
